💉 They will distribute Nanotein’s NanoSpark® products, aimed at enhancing T cells and NK cells for therapies like CAR-T.
🚀 This collaboration aims to streamline workflows and develop innovative solutions for burgeoning cell and gene therapy markets.
Introduction:
The partnership between Sartorius Stedim Biotech and Nanotein Technologies aims to accelerate advancements in cell therapy manufacturing by leveraging innovative solutions, specifically the NanoSpark® platform. Through this collaboration, both organizations seek to enhance the quality and efficiency of immune cell activation and expansion, which are critical for successful cell therapy applications.
- Sartorius Stedim Biotech is investing up to $3 million in Nanotein Technologies to support the commercialization of solutions based on its NanoSpark® platform.
- The partnership includes an exclusive distribution agreement that allows Sartorius to offer Nanotein’s lead T cell and NK cell activators globally.
- The NanoSpark STEM-T Soluble T Cell Activator and NanoSpark GROW-NK Soluble Activator are designed to improve T cell and NK cell expansion respectively.
- This collaboration aims to address challenges in cell therapy manufacturing, including inconsistent yields and reliance on feeder cells.
- Future developments will focus on creating new products tailored for the expanding cell and gene therapy markets.
Conclusion:
The strategic partnership between Sartorius and Nanotein represents a significant step forward in the field of cell therapy. By combining their expertise and resources, they aim to streamline manufacturing processes and enhance the efficacy of immune cell therapies. The implications of this collaboration could lead to more efficient workflows and improved patient outcomes in the rapidly evolving landscape of cancer treatment and regenerative medicine.
